Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

49.02 -0.23 (-0.46%)
Streaming Delayed Price Updated: 11:50 AM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
42 43 Next >
News headline image
FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease ↗
 
Via Benzinga
News headline image
GSK CEO Emma Walmsley On Beating Q4 Earnings ↗
GSK came out with quarterly earnings of $0.64 per share. 
Via Talk Markets
News headline image
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗
Two of the three companies easily beat sales and earnings expectations, but sales fell for the third. 
Via Investor's Business Daily
News headline image
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine ↗
 
Via Benzinga
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
Preview: GlaxoSmithKline's Earnings ↗
 
Via Benzinga
News headline image
Earnings Preview: GSK Q4 Earnings Expected To Decline ↗
This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%. 
Via Talk Markets
GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 1, 2023 ↗
Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion. 
Via Benzinga
News headline image
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs ↗
 
Via Benzinga
News headline image
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK ↗
But Moderna stock didn't move higher on the announcement. 
Via Investor's Business Daily
News headline image
How Could GSK's RSV Vaccine Change its Valuation?
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future. 
Via MarketBeat
News headline image
3 Penny Stocks That Could Make You Filthy Rich ↗
These low-priced equities could deliver enormous returns for risk-tolerant shareholders. 
Via The Motley Fool
News headline image
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗
 
Via Benzinga
News headline image
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock ↗
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market. 
Via The Motley Fool
News headline image
Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review ↗
Microsoft and Google are slashing jobs. Netflix and Tesla jumped. 
Via Investor's Business Daily
News headline image
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
News headline image
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy." 
Via Benzinga
News headline image
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today ↗
Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday. 
Via Benzinga
News headline image
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up ↗
Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines. 
Via Investor's Business Daily
News headline image
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact ↗
WuXi Biologics out-licensed global rights for up to four pre-clinical bi- & multi-specific TCE antibodies to GSK in a $1.5 billion agreement. WuXi Biologics will receive $40 million upfront and up to... 
Via Talk Markets
News headline image
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines ↗
CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock. 
Via InvestorPlace
The Year of the Tripledemic
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which... 
Via TheNewswire.com
Topics Death
News headline image
The Year of the Tripledemic
The Year of the Tripledemic 
Via News Direct
Topics Death
News headline image
What You Missed On Wall Street On Friday ↗
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
News headline image
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca ↗
GSK plc (NYSE: GSK) chief commercial officer Luke Miels says the company is looking at M&A targets that are under-appreciated worth $1 billion-$2.5 billion and avoid getting into a 'bidding war.' 
Via Benzinga
News headline image
Big Health Care Stocks to Watch in the New Year
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now. 
Via MarketBeat
News headline image
7 Drug Stocks That Will Soar in 2023 ↗
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
News headline image
2 Smartest Tech Stocks to Buy in 2022 and Beyond ↗
The tech space is still bursting with opportunities for long-term investors. 
Via The Motley Fool
News headline image
Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says ↗
 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.